In this episode of Boston Scientific Talks, Sandra Nagale, PhD, Director of Digital Health Platforms and Products, breaks down the transformative role of AI within the medical device industry.
Motivated to drive impactful changes, Nagale emphasizes Boston Scientific's unwavering dedication to pioneering breakthrough medical solutions and enhancing patient and physician experiences through AI and emphasizes how products like BeatLogic and LUX-Dx ICM are redefining healthcare by providing actionable, real-time insights.

Navigating the complexities of melding AI with healthcare, Nagale accentuates the necessity for solutions rooted in evidence that genuinely amplifies value. She highlights the urgency to streamline patient experiences, mitigate healthcare worker challenges, and elevate the patient journey. As Boston Scientific spearheads these advancements, Nagale envisions a future where medical devices seamlessly integrate into holistic patient care – from early detection to treatment. Dive into this episode to uncover how Boston Scientific is steering the medtech industry into an AI-augmented future.

Thank you to S3 Connected Health for sponsoring this episode of Boston Scientific Talks. For more information about S3 Connected Health, go to s3connectedhealth.com.

Thank you for listening to the Boston Scientific Podcast.

Subscribe to this podcast on every major podcast platform.

Boston Scientific's Sandra Nagale predicts the future of medtech powered by AI innovations

In this episode of AbbottTalks, Jennifer Jones-McMeans, PhD, Divisional VP of Global Clinical Affairs at Abbott and Brian DeRubertis, MD, Chief, Division of Vascular & Endovascular Surgery at Weill Cornell Medical Center tackle the complexities of treating peripheral arterial disease (PAD) below the knee, particularly chronic limb-threatening ischemia (CLTI), a severe form of PAD that drastically impacts patients' quality of life and longevity.

In the episode, the two discuss Abbott's Esprit BTK System, the first-and-only FDA-approved drug-eluting resorbable scaffold for infrapopliteal CLTI. Dr. Jones-McMeans explains how Esprit BTK works by releasing a drug that prevents artery re-narrowing, crucial for maintaining sustained blood flow and promoting wound healing. 

Later, they walk us through the pivotal LIFE-BTK trial, a significant milestone that demonstrated Esprit's efficacy and led to its FDA approval. They also highlight the importance of including diverse patient populations in clinical trials, particularly those disproportionately affected by PAD, such as African Americans, Latinos, Native Americans, and women. This inclusive approach not only ensures the treatment's effectiveness across varied demographics but also sets a precedent for future trials.

Thank you to Freudenberg Medical for sponsoring this episode of AbbottTalks. For more information on how Freudenberg Medical works with medical device companies, visit www.freudenbergmedical.com.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Jones-McMeans and Dr DeRubertis on PAD below-the-knee, LIFE-BTK trial & Esprit BTK approval

In this episode of the DeviceTalks Weekly Podcast, the DeviceTalks team wraps up the two amazing days of insights and networking at DeviceTalks West.

Tom Salemi, Kayleen Brown and Chris Newmarker welcome guests Alexis Moores, Senior Account Manager, and Steven Thill, Senior Director of Infor, which announced a partnership with NVIDIA at DeviceTalks West, the culmination of a connection forged at DeviceTalks Boston!

Thank you to Infor for sponsoring this episode of DeviceTalks Weekly. To learn how Infor supports MedTech companies visit www.infor.com.

The panel covers a few of the highlights from the event discussion surgical robotics, AI, interventional tools, women’s health.

But first, we unpack the details of PUMPKINGATE!

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Hear the final word about DeviceTalks West: Live recording of DeviceTalks Weekly on-stage

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

In this episode of DeviceTalks Weekly, Tom Salemi and Chris Newmarker tackle some of the weeks’ biggest news including the FDA giving a nod to Distalmotion’s Dexter robot and the Yankees blowing the World Series. 

Distalmotion CEO Greg Roche visits to share his thoughts on both. Then Tom interviews Chad Hoskins, CEO of Phagenesis, a startup developing a neurostimulation device that could help stroke survivors recover.

This week’s Newmaker’s Newsmakers include Medtronic, Masimo, Exactech, Solventum and you already know about this week’s number one.

This episode is sponsored by DeviceTalks Boston. Register now at Boston.DeviceTalks.com.

Thanks for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe now to the DeviceTalks Podcast Network so you don’t miss a future episode.

Phagenesis CEO Hoskins on helping stroke survivors recover; How Distalmotion will target ASCs

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Marwan Berrada, founder and managing partner of Santa Clara-based T45 Labs about how incubators can start new companies at a time when early-stage funding is scarce.

MassDevice Editor Chris Newmarker deliveres his Newmarker’s Newsmakers including GE HealthCare, Zimmer Biomet, Momentis Surgical, Johnson & Johnson MedTech and, of course, the news surrounding HHS.

This episode is sponsored by DeviceTalks Boston. Register at Boston.DeviceTalks.com.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Can T45 Labs use its cross-country connections to bypass MedTech’s early-stage funding shortage?

In this episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker sits down with Wayne Paterson, CEO of Anteris Technologies, a unique start-up that’s approaching the complicated and competitive TAVR market.

Chris Newsmaker and Host Tom Salemi also discuss this week’s Newmarker’s Newsmakers including Medtronic, Boston Scientific, Johnson & Johnson MedTech, NeuroPace and the FDA.

This episode was sponsored by DeviceTalks Minnesota. Register to attend the June 11 event at Minnesota.DeviceTalks.com.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

How an artful pivot and IPO is positioning Anteris Technologies to take on the red hot TAVR space

In this week’s episode of the DeviceTalks Weekly Podcast, MassDevice Editor Chris Newmarker talks with SynCardia CEO Patrick Schnegelsberg and COO Matthew Schuster. Twenty years after FDA approval, SynCardia is the only company with a commercially available total artificial heart, with more than 2,000 implants. Now they're developing what they think will be a game-changer for the technology: a next-gen artificial heart called the Emperor that will be a fully implantable version, without external drivers.

But before the interview Host Tom Salemi gives a quick recap of the MassMedic Symposium and Gala. Then, Chris Newmarker and Senior Editor Danielle Kirsh unpack MassDevice’s new report on surgical robotic companies.

You can download the report for free here. https://www.massdevice.com/gated/massdevices-surgical-robotics-special-report-2025/

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Will SynCardia's Emperor be capable of boldly going where no artificial heart has gone before?

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi interviews Todd Langevin, president of BIOTRONIK Neuro, a familiar name in medical devices with a new approach to alleviating pain through spinal cord stimulation. Langevin, who has spent his career in neuro devices, gives his assessment of the field today, explaining how it’s exceeded his early expectations.

Just before that Tom talks with Joe Mullings of The Mullings Group and Surgical Robotics Expert Steve Bell about the state of the surgical robotics industry. The trio will talk about current leaders, emerging powers, and how a shift toward cardiac surgeons could change the playing field completely.

But to start, MassDevice Editor Chris Newmarker joins Tom for the Newmarker’s Newsmakers, the leading stories from the pages of MassDevice. This week’s newsmakers include Tariffs, Medtronic, Surgical Robotics, Stryker, and BCI company Paradromics.

Thank you for listening to this episode of the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

BIOTRONIK Neuro’s Langevin talks power of connected spinal stim; What’s Next in Surgical Robotics

In this episode of the DeviceTalks Weekly podcast, Host Tom Salemi interviews Alan Lotvin, MD, the CEO and co-founder of Sequel Med Tech, a small company promoting another BIG idea from prolific inventor Dean Kamen. Lotvin, who was formerly a senior executive at CVS/Caremark and PBMs, explains how Twiist, the automated insulin delivery system, could be a game-changer for people with diabetes.

Before the interview, we’ll hear from Ivan Tornos, the CEO and president of Zimmer Biomet. Tornos, who is the opening keynote interview guest at DeviceTalks Boston on April 30 at the Boston Convention & Exhibition Center talks with Salemi and Joe Mullings about the the changes at Zimmer Biomet and in orthopedics.

Register to see Tornos live at Boston.DeviceTalks.com. Use the code mentioned in the podcast to save 25%.

Thanks for listening to the DeviceTalks Weekly Podcast.

Subscribe to the DeviceTalks Podcast Network so you don’t miss a future episode.

Lotvin on why this Sequel AID is better than the original; ZB’s Tornos highlights new tech, ASCs

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Popular tracks tagged #devicetalks